Objective
First‐trimester ultrasound is an important component of prenatal care. We investigated the impact of introducing cell‐free DNA (cfDNA) aneuploidy screening into routine care, on performance of first‐trimester ultrasound.
Methods
Retrospective study of patients who had prenatal care at a tertiary referral center. We compared the performance of any first‐trimester ultrasound between three different aneuploidy screening protocols, used consecutively during the study period: (1) combined first‐trimester screening (FTS); (2) FTS and cfDNA offered together; (3) patients requested to choose between FTS and cfDNA. Secondary outcomes included performance of nuchal translucency (NT), aneuploidy screens and diagnostic genetic procedures.
Results
The number of patients undergoing first‐trimester ultrasound remained similar with the second protocol but decreased in the third (68.7% vs. 40.9%, OR 0.32, 95% CI 0.25–0.4, p < 0.001). Diagnostic procedures decreased between protocol 1 and 2 (7.6% vs. 4.4%, OR 0.59, 95% CI 0.37–0.93, p = 0.02) while NT scans decreased between protocol 2 and 3 (6.8% vs. 1.3%, OR 0.18, 95% CI 0.09–0.4, p < 0.001). The rate of FTS decreased over the study period and less women had cfDNA when they had to choose one method (p < 0.001).
Conclusions
Introducing cfDNA screening as an alternative to FTS, resulted in fewer patients receiving ultrasound in the first‐trimester.